Lantern Pharma shares fall 10.47% premarket despite appointing Dr. Lee Schalop to board.

Lantern Pharma Inc. dropped 10.47% in premarket trading. The company announced the appointment of Dr. Lee Schalop to its Board of Directors, bringing over two decades of experience in biotechnology leadership and financial markets. Dr. Schalop's expertise in precision neurooncology and clinical development, along with his role as a co-founder of Oncoceutics, Inc., is expected to enhance the company's capabilities in oncology drug discovery and development.